日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703

移植后环磷酰胺治疗改善患者报告结局:BMT CTN 1703 的生活质量评估和 2 年结局

Holtan, Shernan G; Bolaños-Meade, Javier; Al Malki, Monzr M; Wu, Juan; Kitko, Carrie L; Reshef, Ran; Rezvani, Andrew R; Shaffer, Brian C; Solh, Melhem M; Yao, Janny M; Runaas, Lyndsey; Elmariah, Hany; Larkin, Karilyn T; El Jurdi, Najla; Gooptu, Mahasweta; Loren, Alison W; Hall, Aric C; Alousi, Amin M; Jamy, Omer; Clark, William; Kean, Leslie; Bhatt, Ami S; Perales, Miguel-Angel; Applegate, Kristy; Efebera, Yvonne Adeduni; Leifer, Eric; Jones, Richard J; Horowitz, Mary M; Mattila, Deborah; Saber, Wael; Hamadani, Mehdi; Martens, Michael J

Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702

尿液无反应标准预测多发性骨髓瘤的无进展生存期:BMT CTN 0702 的事后分析

Banerjee, Rahul; Fritz, Amber R; Akhtar, Othman S; Freeman, Ciara L; Cowan, Andrew J; Shah, Nina; Landau, Heather J; Kumar, Shaji K; Vogl, Dan T; Efebera, Yvonne A; McCarthy, Philip L; Vesole, David H; Mendizabal, Adam; Krishnan, Amrita Y; Somlo, George; Stadtmauer, Edward A; Pasquini, Marcelo C

Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703

移植后环磷酰胺类药物预防移植物抗宿主病对70岁及以上患者的影响:来自BMT CTN 1703的最新进展

Abedin, Sameem; Martens, Michael J; Bolaños-Meade, Javier; Al Malki, Monzr M; Lian, Qinghua; Runaas, Lyndsey; Elmariah, Hany; Gooptu, Mahasweta; Larkin, Karilyn T; Shaffer, Brian C; Loren, Alison W; Solh, Melhem; Alousi, Amin M; Jamy, Omer H; Perales, Miguel-Angel; Rezvani, Andrew; Bhatt, Ami; El Jurdi, Najla; Yao, Janny M; Applegate, Kristy; Kean, Leslie S; Efebera, Yvonne A; Reshef, Ran; Clark, William; Leifer, Eric; Saber, Wael; Horowitz, Mary M; Jones, Richard J; Holtan, Shernan G; Hamadani, Mehdi

Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice

重型再生障碍性贫血患者首选替代供者造血干细胞移植:将证据转化为实践的差距与机遇

Bhatt, Neel S; Borogovac, Azra; Efebera, Yvonne A; DeSalvo, Anna; Devine, Steven M; Foley, Amy; Greco-Stewart, Valerie; Hamilton, Betty K; Heuer, Mykala; Molfenter, Todd; Plastaras, John P; Ragon, Brittany K; Wall, Sarah A; Broglie, Larisa; Juckett, Mark B; Khera, Nandita; Horowitz, Mary M; DeZern, Amy E

A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma

GRIFFIN 研究最终分析的简明语言摘要,该研究评估了达雷妥尤单抗联合来那度胺、硼替佐米和地塞米松治疗新诊断多发性骨髓瘤患者的疗效。

Voorhees, Peter M; Sborov, Douglas W; Laubach, Jacob; Kaufman, Jonathan L; Reeves, Brandi; Rodriguez, Cesar; Silbermann, Rebecca; Costa, Luciano J; Anderson, Larry D Jr; Nathwani, Nitya; Shah, Nina; Bumma, Naresh; Efebera, Yvonne A; Holstein, Sarah A; Costello, Caitlin; Jakubowiak, Andrzej; Wildes, Tanya M; Orlowski, Robert Z; Shain, Kenneth H; Cowan, Andrew J; Dinner, Shira; Gries, Katharine S; Pei, Huiling; Cortoos, Annelore; Patel, Sharmila; Lin, Thomas S; Usmani, Saad Z; Richardson, Paul G

Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Treatment Priorities and Novel Therapies

医疗服务提供者和复发/难治性多发性骨髓瘤患者对治疗重点和新型疗法的看法

Ailawadhi, Sikander; Biru, Yelak; Clavreul, Solène; San Miguel, Maite; Cormier, Nicolas; Efebera, Yvonne; Merz, Maximilian; Sato, Anna; Zeanah, Cathy; Watkins, Jack L; Farrell, James; Goldman, Erinn Hoag; Popat, Rakesh

Semi-parametric testing for ordinal treatment effects in time-to-event data via dynamic Dirichlet process mixtures of the inverse-Gaussian distribution

利用逆高斯分布的动态狄利克雷过程混合模型,对生存时间数据中的有序处理效应进行半参数检验

Race, Jonathan A; Ruppert, Amy S; Efebera, Yvonne; Pennell, Michael L

Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival

自体造血干细胞移植和来那度胺维持治疗1年后多发性骨髓瘤的微小残留病灶状态与长期总生存期相关

Pasquini, Marcelo C; Wallace, Paul K; Logan, Brent; Kaur, Manmeet; Tario, Joseph D; Howard, Alan; Zhang, Yali; Brunstein, Claudio; Efebera, Yvonne; Geller, Nancy; Giralt, Sergio; Hari, Parameswaran; Horowitz, Mary M; Koreth, John; Krishnan, Amrita; Landau, Heather; Somlo, George; Shah, Nina; Stadtmauer, Edward; Vogl, Dan T; Vesole, David H; McCarthy, Philip L; Hahn, Theresa

Correction: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401

更正:树突状细胞/骨髓瘤融合疫苗联合来那度胺维持治疗多发性骨髓瘤一线自体造血干细胞移植后的随机II期试验:BMT CTN 1401

Chung, David J; Shah, Nina; Wu, Juan; Logan, Brent; Bisharat, Lina; Callander, Natalie; Cheloni, Giulia; Anderson, Kenneth; Chodon, Thinle; Dhakal, Binod; Devine, Steve; Dutt, Poorvi Somaiya; Efebera, Yvonne; Geller, Nancy; Ghiasuddin, Haider; Hematti, Peiman; Holmberg, Leona; Howard, Alan; Johnson, Bryon; Karagkouni, Dimitra; Lazarus, Hillard M; Malek, Ehsan; McCarthy, Philip; McKenna, David; Mendizabal, Adam; Nooka, Ajay; Munshi, Nikhil; O'Donnell, Lynn; Patel, Krina; Rapoport, Aaron P; Reese, Jane; Rosenblatt, Jacalyn; Soiffer, Robert; Stroopinsky, Dina; Uhl, Lynne; Vlachos, Ioannis S; Waller, Edmund K; Young, James W; Pasquini, Marcelo C; Avigan, David

ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study

ANCHOR:melflufen联合地塞米松和daratumumab或硼替佐米治疗复发/难治性多发性骨髓瘤:一项I/IIa期研究的最终结果

Ocio, Enrique M; Efebera, Yvonne A; Hájek, Roman; Straub, Jan; Maisnar, Vladimir; Eveillard, Jean-Richard; Karlin, Lionel; Mateos, María-Victoria; Oriol, Albert; Ribrag, Vincent; Richardson, Paul G; Norin, Stefan; Obermüller, Jakob; Bakker, Nicolaas A; Pour, Luděk